Ropes & Gray Represents Shape Therapeutics in Gene Therapy Collaboration With Roche Worth Up to $3 Billion
Ropes & Gray advised Shape Therapeutics in a strategic research collaboration and license agreement with Roche worth up to $3 billion to use Shape’s RNA-editing platform and adeno-associated virus technology to identify and develop treatments for Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The deal was announced on August 24. BioWorld notes that this is one of the biggest collaboration deals of the year.
The Ropes & Gray team was led by IP transactions partner Hannah England (Freeman) and associate Rob Treut and included IP transactions partner David McIntosh (all of Boston).